UNICREDIT BANK/CALL/AMGEN/450/0.1/17.12.25 | Market Closed - Börse Stuttgart 19:18:56 17/05/2024 BST | ||
| 0.93 EUR | -3.12% |
|
| Current month | +151.35% | ||
| 1 month | +190.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
More news
| Date | Price | Change |
|---|---|---|
| 17/05/24 | 0.93 | -3.12% |
| 16/05/24 | 0.96 | -4.95% |
| 15/05/24 | 1.01 | +14.77% |
| 14/05/24 | 0.88 | +7.32% |
| 13/05/24 | 0.82 | -4.65% |
Delayed Quote Börse Stuttgart
Last update May 17, 2024 at 07:18 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1H7K |
| ISIN | DE000HD1H7K9 |
| Date issued | 28/12/2023 |
| Strike | 450 $ |
| Maturity | 17/12/2025 (579 Days) |
| Parity | 10 : 1 |
| Emission price | 0.69 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.16 € |
|---|---|
| Lowest since issue | 0.2 € |
| Spread | 0.02 € |
| Spread % | 2.13% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
312.5
USD
Average target price
314.1
USD
Spread / Average Target
+0.51%
- Stock Market
- Warrants
- Warrant
